Across TCGA pan-cancer cohorts, TRMT2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRMT2B data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TRMT2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT2B expression acts as an unfavorable survival marker.
BRCA, BLCA, and PCPG are the cancer types where TRMT2B Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.